Welcome to our dedicated page for Livanova Plc news (Ticker: LIVN), a resource for investors and traders seeking the latest updates and insights on Livanova Plc stock.
LivaNova PLC (NASDAQ: LIVN) is a global medical technology company headquartered in London, focused on select neurological and cardiac conditions. This news page aggregates company announcements, clinical updates, investor communications, and other disclosures that LivaNova issues through press releases and related channels.
Readers can find coverage of LivaNova’s neuromodulation activities, including developments in VNS Therapy for Drug‑Resistant Epilepsy and results from the CORE‑VNS real‑world study. News items also describe health economics analyses, reimbursement decisions affecting VNS Therapy procedures under U.S. Medicare programs, and scientific presentations at major epilepsy meetings.
The feed also includes updates on LivaNova’s cardiopulmonary business and its heart‑lung support technologies, as well as information on its work in obstructive sleep apnea through proximal hypoglossal nerve stimulation and the aura6000 investigational system. Articles may highlight data from randomized controlled trials, long‑term follow‑up analyses, and presentations at specialized surgical sleep and medical conferences.
In addition, investors can follow LivaNova’s participation in healthcare investment conferences, Investor Day events, and quarterly financial result announcements, which the company often distributes via press release and webcasts. By reviewing this page, users can track how LivaNova communicates about its core Epilepsy and Cardiopulmonary businesses, its research programs, and its long‑range strategic plans.
For anyone researching LIVN stock or monitoring developments in medical technology for neurological and cardiac conditions, this news page offers a centralized view of LivaNova’s public announcements over time.
FAQ
What is the current stock price of Livanova Plc (LIVN)?
What is the market cap of Livanova Plc (LIVN)?
